Skip to main content
NCBI home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1983 Mar 19;286(6369):923–925. doi: 10.1136/bmj.286.6369.923

Rifampicin reduces effectiveness and bioavailability of prednisolone.

W A McAllister, P J Thompson, S M Al-Habet, H J Rogers
PMCID: PMC1547305  PMID: 6403136

Abstract

Rifampicin is an inducer of hepatic drug metabolising enzymes. This results in interactions with several drugs including oral anticoagulants, hypoglycaemics, and contraceptives. Concurrent treatment with prednisolone and rifampicin is given when tuberculosis coexists with a disease that is sensitive to steroids, when the diagnosis is uncertain, or occasionally in the treatment of severe tuberculosis. Two patients with respiratory disease were treated with both drugs: their condition improved considerably after rifampicin was withdrawn. Seven patients were then studied to assess the effect of rifampicin on the pharmacokinetics of prednisolone. Overall, rifampicin increased the plasma clearance of prednisolone by 45% and reduced the amount of drug available to the tissues (area under the plasma concentration time curve) by 66%. The effectiveness of prednisolone may be considerably reduced when rifampicin and prednisolone are used in combination.

Full text

PDF
923

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acocella G., Bonollo L., Garimoldi M., Mainardi M., Tenconi L. T., Nicolis F. B. Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease. Gut. 1972 Jan;13(1):47–53. doi: 10.1136/gut.13.1.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Al-Habet S. M., McAllister W. A., Collins J. V., Rogers H. J. Comparison of radioimmunoassay and thin layer chromatographic assay methods for estimation of plasma prednisolone concentrations. J Pharmacol Methods. 1981 Sep;6(2):137–142. doi: 10.1016/0160-5402(81)90036-x. [DOI] [PubMed] [Google Scholar]
  3. Al-Habet S., Rogers H. J. Pharmacokinetics of intravenous and oral prednisolone. Br J Clin Pharmacol. 1980 Nov;10(5):503–508. doi: 10.1111/j.1365-2125.1980.tb01796.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Buffington G. A., Dominguez J. H., Piering W. F., Hebert L. A., Kauffman H. M., Jr, Lemann J., Jr Interaction of rifampin and glucocorticoids. Adverse effect on renal allograft function. JAMA. 1976 Oct 25;236(17):1958–1960. [PubMed] [Google Scholar]
  5. Hendrickse W., McKiernan J., Pickup M., Lowe J. Rifampicin-induced non-responsiveness to corticosteroid treatment in nephrotic syndrome. Br Med J. 1979 Feb 3;1(6159):306–306. doi: 10.1136/bmj.1.6159.306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Jezequel A. M., Orlandi F., Tenconi L. T. Changes of the smooth endoplasmic reticulum induced by rifampicin in human and guinea-pig hepatocytes. Gut. 1971 Dec;12(12):984–987. doi: 10.1136/gut.12.12.984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Morrison P. J., Bradbrook I. D., Rogers H. J. Plasma prednisolone levels from enteric and non-enteric coated tablets estimated by an original technique. Br J Clin Pharmacol. 1977 Oct;4(5):597–603. doi: 10.1111/j.1365-2125.1977.tb00792.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. O'Reilly R. A. Interaction of sodium warfarin and rifampin. Studies in man. Ann Intern Med. 1974 Sep;81(3):337–340. doi: 10.7326/0003-4819-81-3-337. [DOI] [PubMed] [Google Scholar]
  9. Ohnhaus E. E., Park B. K. Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin. Eur J Clin Pharmacol. 1979 Mar 26;15(2):139–145. doi: 10.1007/BF00609878. [DOI] [PubMed] [Google Scholar]
  10. Schoene B., Fleischmann R. A., Remmer H., von Oldershausen H. F. Determination of drug metabolizing enzymes in needle biopsies of human liver. Eur J Clin Pharmacol. 1972 Mar;4(2):65–73. doi: 10.1007/BF00562499. [DOI] [PubMed] [Google Scholar]
  11. Tanner A., Bochner F., Caffin J., Halliday J., Powell L. Dose-dependent prednisolone kinetics. Clin Pharmacol Ther. 1979 May;25(5 Pt 1):571–578. doi: 10.1002/cpt1979255part1571. [DOI] [PubMed] [Google Scholar]
  12. Toverud E. L., Boobis A. R., Brodie M. J., Murray S., Bennett P. N., Whitmarsh V., Davies D. S. Differential induction of antipyrine metabolism by rifampicin. Eur J Clin Pharmacol. 1981;21(2):155–160. doi: 10.1007/BF00637517. [DOI] [PubMed] [Google Scholar]
  13. Zilly W., Breimer D. D., Richter E. Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. Eur J Clin Pharmacol. 1975 Dec 19;9(2-3):219–227. doi: 10.1007/BF00614021. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES